Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Rituximab Plus Cladribine in Advanced or Relapsed MALT Lymphoma
2008-000767-41Phase 2Completed
- Sponsor
- AGMT
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and cladribine in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by AGMT. Primary endpoint: Objective response rate. Started Apr 2008; status: completed.
02
Drugs
rituximabcladribine
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2008-000767-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000767-41.